Recent Finacing
Recent Raise
Ashvattha Therapeutics develops hydroxyl dendrimer therapeutics that chemically conjugate drugs to selectively target and reprogram activated inflammatory cells, crossing blood-brain and blood-retinal barriers for ophthalmology and neurology.
